Crossmark

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?

Crossref DOI link: https://doi.org/10.1038/tpj.2017.21

Published Online: 2017-06-13

Published Print: 2017-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Verbelen, M http://orcid.org/0000-0001-7390-3102
Weale, M E

Lewis, C M
License Information

Text and Data Mining valid from 2017-06-13
More Information

Article History

Received: 21 September 2016

Revised: 15 February 2017

Accepted: 14 April 2017

First Online: 13 June 2017

Competing interests

: MV is funded by a studentship from the Medical Research Council and Eli Lilly and Company Ltd. MEW is a part-time employee of Genomics plc. CML declares no conflict of interest.